BMO cuts UiPath stock price target on AI monetization concerns By Investing.com

BMO cut UiPath's price target to $14 from $17 (maintaining Market Perform) and BofA cut its target to $12 from $14 (Underperform) after UiPath’s fiscal Q4; BMO flagged the need for more evidence of sustained AI monetization. UiPath beat Q4 consensus and reported an 83% gross margin, ~13% revenue growth over the last 12 months, and fiscal 2027 ARR growth guidance of ~10.8% (net new ARR $200M vs prior year $187M). Management announced an expanded Deloitte alliance for an AI-powered Agentic ERP product, but analyst concerns on AI monetization and weaker implied billings keep the tone mixed.

Analysis

UiPath’s push to productize AI through partner-led, upstack offerings changes the competitive map: services firms and ERP incumbents become indirect beneficiaries while pure-play RPA vendors face a two-front challenge—defending core automation stickiness while proving a new usage-driven revenue stream. That raises implementation and sales mix second-order effects — higher upfront services and SI co-sell costs can depress near-term billings even as long-term ARR quality improves, shifting the timing of cash conversion.

The critical investor debate is not whether AI features exist but whether AI can be consistently monetized at scale inside large accounts. Monetization will show up as expanding per-customer monthly run-rate, sustained uplift in consumption metrics, and repeatable annualized contract expansions; absence of all three for multiple quarters should keep multiples under pressure. Conversely, a small set of multi-hundred-million-dollar enterprise commitments tied to measurable consumption could act as a fast re-rating catalyst.

From a financial-mechanic perspective, watch billing composition and churn-adjusted net retention rather than headline ARR alone: moves to usage pricing can create near-term recognition volatility and press operating leverage if sales/consulting costs step up. Over 12–24 months this creates a bifurcation — either margin expansion as AI becomes software-native, or margin compression if go-to-market remains services-heavy and peers compress multiples, making M&A a likely strategic exit for weak public names.

Timewise, expect market reactions in days around guidance/billing disclosures, meaningful validation or repudiation over 3–6 quarters of consistent AI-derived revenue growth, and structural consolidation over 12–36 months if valuation disconnects persist.

Key Decisions for Investors

• Short PATH equity (or buy 3–6 month ATM puts) sized 1–2% portfolio — thesis: near-term multiple compression if AI monetization signals remain mixed. Target 2:1 downside-to-premium payoff; cap position size to limit gamma risk around quarterly prints.
• Pair trade: short PATH / long NICE (NICE) or long ACN (Accenture) for 6–12 months — thesis: shift from product-selling risk to services & SI capture. Expect asymmetric payoff if vendors monetize through partnerships; hedge beta to sector with equal notional exposure.
• Event-driven long call spread on PATH (12-month) as a binary upside play — buy a deep OTM-to-ATM call spread (debit) to limit downside while capturing re-rate if a marquee enterprise shows measurable consumption. Keep position size <1% portfolio given low probability/high payoff.
• Long ORCL or MSFT (6–24 months) as strategic-acquirer optionality hedge — rationale: incumbents can buy automation/IP cheaply if consolidation accelerates; this captures upside from sector M&A while providing defensive exposure to ERP/cloud capture.